Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. This two-part webinar series will present recent developments in oligonucleotide chemistry, biology, DMPK, toxicological assessment, manufacture and formulation. In this first session we will have presentations from experts involved in providing state of the art technical support to the discovery stages of an oligonucleotide therapeutic program. We will discuss the synthesis and modification of oligonucleotides, design and execution of suitable in vitro and in vivo assays, and methods for determining pharmacokinetic parameters. We will also hear about state of the art discovery strategies with a case history from an exciting young biotech company employing oligonucleotides to create impactful therapeutics. Finally our expert panel will be available for a question and answer session.